Contract research organisation Broughton has once again completed inspections by the United Kingdom Accreditation Service (UKAS) and the Medicines and Healthcare products Regulatory Agency (MHRA) with no major or critical findings. The audits, conducted in August and September 2025, extend the company’s 19-year record of full regulatory compliance and reaffirm its standing in the UK’s pharmaceutical and life sciences sectors.
The three-day UKAS inspection evaluated Broughton’s adherence to ISO 17025, the international standard for testing and calibration laboratories. This benchmark ensures technical competence, data integrity, and traceability. The absence of major findings demonstrates Broughton’s strong quality management systems and its ability to deliver accurate and consistent results.
The two-day MHRA audit reviewed compliance with Good Manufacturing Practice (GMP), focusing on laboratory operations, systems, and documentation related to patient safety and product quality. The successful result reflects Broughton’s commitment to maintaining the highest scientific and operational standards across its laboratories.
“Our approach to audits has always been grounded in openness,” said Emmet Tilley, Associate Director of Quality at Broughton. “We engage fully with inspectors because transparency builds trust and keeps us evolving. Every inspection is an opportunity to refine how we work, strengthen our systems, and align our practices with the expectations of both regulators and clients. Sustaining compliance for nearly two decades isn’t just a measure of quality management, it’s a reflection of the culture at Broughton that values rigor and continuous improvement.”
The results come at a time of increasing global scrutiny of data integrity and manufacturing standards. A 2025 report by the International Organization for Standardization noted that ISO 17025 compliance has become more critical for laboratories managing complex global supply chains, while the MHRA’s GMP standards remain central to ensuring international product safety and efficacy.
“When customers know that our data withstands the highest levels of scrutiny, they can move forward with greater speed and assurance,” said Chris Allen, Chief Executive Officer. “It provides confidence in the knowledge their development pipelines meet the most demanding international expectations. That’s what drives our investment in capability, enabling faster development of products that improve lives.”
Broughton continues to invest in expanding its technical expertise and digital infrastructure to support compliance and innovation. Advanced analytical techniques and streamlined data management systems now strengthen traceability and reproducibility, enhancing client confidence.
Key achievements from the inspections include:
- No major findings: Both UKAS and MHRA audits concluded with zero critical or major observations.
- 19-year compliance record: Broughton has maintained dual accreditation since 2006 without interruption.
- Enhanced client trust: Reliable compliance enables faster, safer product development for global clients.
Broughton’s continued success in regulatory inspections underscores its position as a trusted partner in pharmaceutical and life sciences research. Its focus on continuous improvement and scientific integrity ensures the company remains well positioned to meet the growing demands of the industry.
